Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ACET
- Price
- 8.40
- Stock movement up
- +0.19 (2.83%)
- Company name
- Adicet Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 66.34M
- Ent value
- 68.57M
- Price/Sales
- 10.20
- Price/Book
- 0.61
- Div yield
- 0.58%
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -23.27%
- 1 year return (CAGR)
- 697.46%
- 3 year return (CAGR)
- -5.58%
- 5 year return (CAGR)
- -13.13%
- 10 year return (CAGR)
- -
Last updated: 2026-02-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ACET does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 10.20 |
| Price to Book | 0.61 |
| EV to Sales | 10.54 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 9.60M |
| EPS (TTM) | -1.26 |
| FCF per share (TTM) | -1.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.51M |
| Gross profit (TTM) | -27.00K |
| Operating income (TTM) | -120.97M |
| Net income (TTM) | -115.01M |
| EPS (TTM) | -1.26 |
| EPS (1y forward) | -11.09 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -0.41% |
| Operating margin (TTM) | -1859.39% |
| Profit margin (TTM) | -1767.81% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 29.10M |
| Net receivables | 169.00K |
| Total current assets | 106.49M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 56.89M |
| Total assets | 140.48M |
| Accounts payable | 4.29M |
| Short/Current long term debt | 15.54M |
| Total current liabilities | 18.94M |
| Total liabilities | 31.34M |
| Shareholder's equity | 109.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -98.44M |
| Capital expenditures (TTM) | 1.92M |
| Free cash flow (TTM) | -100.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -105.38% |
| Return on Assets | -81.87% |
| Return on Invested Capital | -102.32% |
| Cash Return on Invested Capital | -89.28% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.76 |
| Daily high | 7.30 |
| Daily low | 6.72 |
| Daily Volume | 237K |
| All-time high | 145.95 |
| 1y analyst estimate | 61.50 |
| Beta | 1.56 |
| EPS (TTM) | -1.26 |
| Dividend per share | 0.04 |
| Ex-div date | 21 Sep 2018 |
| Next earnings date | 5 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ACET | S&P500 | |
| Current price drop from All-time high | -94.24% | -0.89% |
| Highest price drop | -99.69% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -84.59% | -10.86% |
| Avg time to new high | 202 days | 12 days |
| Max time to new high | 2005 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
66.34M
Marketcap category
Small-cap
Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Employees
152
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page